Latest Clinical Trials News

Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.

Neurotech International has inked a development deal with RH Farma to produce a pharmaceutical-grade cannabinoid drug targeting pediatric neurodevelopmental disorders, leveraging advanced European extraction technology.

Island Pharmaceuticals has successfully completed patient dosing in the Phase 2b therapeutic arm of its PROTECT clinical trial for ISLA-101, targeting dengue fever treatment. High-level results are expected within two months, potentially advancing a significant antiviral candidate.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

Argenica Therapeutics reported a 16% reduction in half-year losses to $1.19 million, buoyed by a 29% increase in other income largely from R&D tax incentives, as it advances its neuroprotective drug development.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

Clarity Pharmaceuticals has expanded its breast cancer pipeline by introducing 64/67Cu-SAR-trastuzumab, supported by promising pre-clinical data and a new supply agreement for trastuzumab, aiming to address the unmet needs in HER2-positive breast cancer treatment.

Alterity Therapeutics has raised A$40 million through a two-tranche placement to advance its lead compound ATH434 for neurodegenerative diseases, including Multiple System Atrophy and Parkinson's disease.

Arovella Therapeutics has requested a voluntary suspension of its ASX-listed securities pending a material announcement on a capital raising, expected by 17 February 2025.

BlinkLab has secured North Shore Pediatric Therapy as the second US clinical site in its autism diagnostic study, enhancing recruitment and data quality with a leading Chicago-based specialist.

PYC Therapeutics has secured regulatory approval to initiate human trials of PYC-003, a novel drug candidate targeting the root cause of Polycystic Kidney Disease (PKD). Initial safety and efficacy data are expected within 2025, marking a critical step in addressing a disease affecting millions worldwide.

Radiopharm Theranostics' RAD 101 radiotracer demonstrates high sensitivity in detecting brain metastases using a novel PET-mpMRI approach, with a Phase 2b trial now recruiting in the US.